Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients
Cheng‐Zhao Weng, Rongcheng Xie, Guanjie Han, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 649-662
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria‐Inti Metzendorf, Rebecca Kuehn, et al.
Cochrane library (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 22
Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review
Piotr Rzymski, Maria Pokorska‐Śpiewak, Teresa Jackowska, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1502-1502
Open Access | Times Cited: 19
Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review
Romina Quercia, Giovanni Di Perri, C. Pein, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 5, pp. 1005-1017
Open Access | Times Cited: 5
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Haiyu Wang, Guangying Cui, Ming Cheng, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study
Antonio Russo, Mariantonietta Pisaturo, Chiara Cacace, et al.
Pathogens (2025) Vol. 14, Iss. 3, pp. 216-216
Open Access
Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022
Jong-Mu Kim, Min‐Gyu Yoo, Soon Jong Bae, et al.
Journal of Korean Medical Science (2023) Vol. 38, Iss. 27
Open Access | Times Cited: 12
Population pharmacokinetic modeling and simulation for nirmatrelvir exposure assessment in Chinese older patients with COVID-19 infection
Yuchen Qu, Cunjin Su, Zheng Xiang, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 189, pp. 106535-106535
Open Access | Times Cited: 10
Key Essentials during the Transition from the Acute Phase of the COVID-19 Pandemic
Piotr Rzymski, Maria Pokorska‐Śpiewak, Teresa Jackowska, et al.
(2023)
Open Access | Times Cited: 10
COVID-19: An Update on the Latest Therapeutic Agents
Ke-Yan Loo, Loh Teng‐Hern Tan, Jodi Woan‐Fei Law, et al.
Progress In Microbes & Molecular Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 9
Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China
Pulin Li, Ling Huang, Rui Han, et al.
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 6, pp. 469-477
Closed Access | Times Cited: 2
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 2
Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study
Abiden Kapar, Songsong Xie, Zihao Guo, et al.
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 7, pp. 569-577
Closed Access | Times Cited: 1
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study
Huan Zhang, Xiaojiao Tan, Zheng Zhang, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study
Yue Guo, Yifei Guo, Huajian Ying, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
Chengyi Hu, Wen-Shuai Cui, Yi Lei, et al.
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 7797-7808
Open Access | Times Cited: 4
Evaluating Nirmatrelvir-Ritonavir (Paxlovid®) in Outpatient COVID-19 Treatment: Safety, Tolerability, and Adherence Insights from Primary Healthcare Clinics
Zahirah Zaharuddin, Nur Sabiha Md Hus, Mahmathi Karuppannan
Research Square (Research Square) (2024)
Open Access
Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study
Dong-Hwi Kim, Min‐Gyu Yoo, Na-Young Kim, et al.
Osong Public Health and Research Perspectives (2024) Vol. 15, Iss. 2, pp. 137-149
Open Access
Clinical Characteristics and Booster Vaccine Effectiveness of the Omicron Variant
Lijun Sun, Biye Zhou, Yijia Guo, et al.
Research Square (Research Square) (2024)
Open Access
Synthesis, characterization, cytotoxicity, and antiviral activity of new coumarin analogues against coronavirus
Mohammad Auwal Sa’ad, Manickam Ravichandran, Pattabhiraman Lalitha, et al.
Results in Chemistry (2024) Vol. 10, pp. 101702-101702
Open Access
Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients
Na Chen, Xuben Yu, Lu Li, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 4055-4065
Open Access
Clinical Symptom Influence on The Time of Nucleic Acid Conversion to Negative in COVID-19 Patients with SARS-CoV-2 Omicron Variant: A Retrospective Observational Study
Hui Feng, Xiang Hong, Shanhu Qiu, et al.
Research Square (Research Square) (2024)
Open Access
D-dimer for efficacy prediction in COVID-19 patients treated with paxlovid
Daishi Li, Qingrong Wu, Wenrui Lin, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Lijun Sun, Biye Zhou, Yijia Guo, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Challenges in Treating Pediatric Cancer Patients during the COVID-19 Pandemic: Balancing Risks and Care
Juan Luis Chávez‐Pacheco, Manuel Castillejos‐López, Laura M. Hernández-Regino, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 690-690
Open Access
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients
Zahirah Zaharuddin, Nur Sabiha Md Hussin, Mahmathi Karuppannan
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top